Full Press Release Details
Marker Therapeutics Announces Clinical
Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
- February 25, 2019 - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology
company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies
and solid tumor indications, today announced updated data from four clinical trials using the Company's multi-antigen targeted
T cell (MultiTAA) therapies. The data was reviewed in oral and poster presentations at the Transplantation & Cellular Therapy
Meetings of ASBMT and CIBMTR 2019 which took place in Houston, TX from February 20-24. Among the highlights, were results from
an ongoing study including patients with acute myeloid leukemia (AML), which were reviewed in an oral presentation by Dr. Premal
Lulla, M.B.B.S., Assistant Professor of Medicine, Baylor College of Medicine.
"We continue to be highly encouraged
by the clinical results we've seen to date with our MultiTAA therapies. In AML, we believe we are seeing increasing evidence
of meaningful therapeutic benefit for patients with limited treatment alternatives. Our MultiTAA therapy appears to be safe and
well-tolerated with the potential to mediate a meaningful anti-tumor effect, in addition to demonstrating a compelling correlation
between therapeutic responses, with superior in vivo expansion of our T cells," said Peter L. Hoang, President &
CEO of Marker Therapeutics. "Similarly, the studies ongoing in acute lymphoblastic leukemia, or ALL, lymphoma and multiple
myeloma continue to demonstrate positive results, and are supportive of the data we presented at ASH in December, importantly with
no additional disease relapses. Overall, this data update and our update at ASH 2018 in December collectively have increased our
total reported number of patients to 78 as compared to the 57 patients we had reported as of November."
In Arm A of the AML study, 13 patients
at Baylor College of Medicine were dosed with MultiTAA T cells as a maintenance therapy after receiving allogeneic stem cell transplant.
Results demonstrated:
In Arm B of the AML study, 6 patients suffering
from active disease with relapsed/refractory (r/r) AML have been treated, with 1 patient having been treated twice for active disease
with MultiTAA T cells;
data from ongoing lymphoma and multiple myeloma trials, also presented in an oral presentation at the meeting were updated results
from an ongoing study in ALL. Updates from this trial included:
very excited about the results we are seeing in our early clinical trials. For patients with r/r AML, we believe that MultiTAA
therapies may produce meaningful improvements in overall survival of patients who historically have had a dire prognostic outlook,"
stated Mythili Koneru, Senior Vice President of Clinical Development at Marker Therapeutics. "In adjuvant settings for patients
currently in remission, I believe our early clinical results suggest that we may be providing significant additional protection
against relapse and disease recurrence."
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies
for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on
the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets)
and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets
and acts to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically
engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less
expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit.
As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current
gene-modified CAR-T and TCR-based therapies.
Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid
tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110)
for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology
named PolyStart that can enhance the ability of the immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904) 862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance
or other matters, are "forward-looking statements". Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities
relating to our non-engineered multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart
program; the effectiveness of these programs or the possible range of application and potential curative effects and safety in
the treatment of diseases; and, the timing and success of our clinical trials, as well as multi-tumor antigen specific T cell clinical
trials conducted by our collaborators. Forward-looking statements are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings
which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update our forward-looking statements whether
as a result of new information, future events or otherwise, after the date of this press release.
Marker Therapeutics, Inc.